PRQR

1.65

3.51% -0.06

Handel nachbörslich: 1.66 0.01 +0.61%

Proqr Therapeutics N V (PRQR)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose

Schlusskurs vom Vortag:

$1.71

Offen:

$1.72

24-Stunden-Volumen:

584.79K

Relative Volume:

0.55

Marktkapitalisierung:

$232.85M

Einnahmen:

$15.53M

Nettoeinkommen (Verlust:

$-52.71M

KGV:

-3.2836

EPS:

-0.5025

Netto-Cashflow:

$-59.00M

1W Leistung:

-9.84%

1M Leistung:

-30.67%

6M Leistung:

+4.43%

1J Leistung:

-20.29%

1-Tages-Spanne:

$1.63

$1.72

1-Wochen-Bereich:

$1.63

$1.91

52-Wochen-Spanne:

$1.33

$3.10

Proqr Therapeutics N V Stock (PRQR) Company Profile

Firmenname

Proqr Therapeutics N V

Sektor

Healthcare (1067)

Branche

Biotechnology (595)

Telefon

Adresse

Mitarbeiter

187

Twitter

@proqr

Nächster Verdiensttermin

2026-11-05

Neueste SEC-Einreichungen

PRQR's Discussions on Twitter

Compare PRQR vs VRTX, REGN, MRNA, ARGX, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PRQR Proqr Therapeutics N V	1.65	232.85M	15.53M	-52.71M	-59.00M	-0.5025
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-12	Fortgesetzt	Oppenheimer	Outperform
2025-04-29	Fortgesetzt	Cantor Fitzgerald	Overweight
2025-04-29	Eingeleitet	Evercore ISI	Outperform
2025-03-10	Hochstufung	Citigroup	Neutral → Buy
2025-01-10	Eingeleitet	Oppenheimer	Outperform
2024-10-29	Hochstufung	Raymond James	Outperform → Strong Buy
2023-11-08	Hochstufung	Chardan Capital Markets	Neutral → Buy
2023-03-30	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2022-12-22	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2022-02-14	Herabstufung	Citigroup	Buy → Neutral
2022-02-11	Herabstufung	Raymond James	Strong Buy → Mkt Perform
2022-02-11	Herabstufung	Stifel	Buy → Hold
2022-02-01	Eingeleitet	Raymond James	Strong Buy
2021-05-03	Eingeleitet	Stifel	Buy
2021-03-25	Bestätigt	Citigroup	Buy
2020-11-03	Fortgesetzt	Cantor Fitzgerald	Overweight
2019-03-12	Bestätigt	Chardan Capital Markets	Buy
2018-12-19	Eingeleitet	RBC Capital Mkts	Outperform
2018-11-15	Eingeleitet	Citigroup	Buy
2018-09-19	Eingeleitet	Evercore ISI	Outperform
2017-09-26	Bestätigt	JMP Securities	Mkt Outperform
2016-06-20	Eingeleitet	Chardan Capital Markets	Neutral
2014-10-15	Eingeleitet	Deutsche Bank	Buy
2014-10-13	Eingeleitet	H.C. Wainwright	Buy

Alle ansehen

Proqr Therapeutics N V Aktie (PRQR) Neueste Nachrichten

Sep 23, 2026

ProQR names AI executives as clinical data nears By Investing.com - Investing.com Canada

Sep 23, 2026

ProQR Taps AI Leaders Chris Hart and Thomas Wolf to Accelerate Axiomer RNA Editing Pipeline - TipRanks

Sep 23, 2026

ProQR names AI executives as clinical data nears - Investing.com

Sep 23, 2026

Hugging Face co-founder joins ProQR (PRQR) to drive AI drug discovery - Stock Titan

Sep 23, 2026

Nvidia agreed to buy Hugging Face for $12.9B. Its co-founder will advise ProQR on AI. - Stock Titan

Sep 23, 2026

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Sep 23, 2026

Sep 11, 2026

Price to sales forward of ProQR Therapeutics N.V. – SWB:0PQ - TradingView

Sep 11, 2026

Sep 10, 2026

Obesity Market to Witness Strong Growth and Significant Market Expansion by 2036 – DelveInsight | Rhythm Pharma, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical - Barchart.com

Sep 10, 2026

ProQR Therapeutics Initiates AX-0811 Clinical Trial Following First Participant Dosing - Kalkine Media

Sep 10, 2026

ProQR Therapeutics N.V.ADR Key Financial Ratios – Valuation, Profitability & More - Value Research

Sep 10, 2026

Sep 09, 2026

ProQR at Cantor conference: RNA editing pipeline gains speed By Investing.com - Investing.com Australia

Sep 09, 2026

ProQR doses first participant in AX-0811 phase 1 trial By Investing.com - Investing.com South Africa

Sep 09, 2026

ProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease Treatment - marketscreener.com

Sep 09, 2026

ProQR doses first participant in AX-0811 phase 1 trial - investing.com

Sep 09, 2026

ProQR Doses First Participant in Phase 1 Trial of AX-0811 for Cholestatic Liver Diseases - TipRanks

Sep 09, 2026

ProQR Announces First Participant Dosed in Phase 1 Study of - GlobeNewswire

Sep 09, 2026

ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving AverageShould You Sell? - marketbeat.com

Sep 09, 2026

ProQR at Cantor conference: RNA editing pipeline gains speed - Investing.com

Sep 09, 2026

symbol__ Stock Quote Price and Forecast - CNN

Sep 09, 2026

Sep 07, 2026

Enterprise value to EBIT forward of ProQR Therapeutics N.V. – NASDAQ:PRQR - TradingView

Sep 07, 2026

Sep 03, 2026

CureVac NV (CVAC) Peer Comparison – Compare with Others - Value Research

Sep 03, 2026

Sep 02, 2026

ProQR to Participate in Upcoming Investor Conferences in September 2026 - markets.businessinsider.com

Sep 02, 2026

Qiagen N.V.ADR Peer Comparison – Compare with Others - Value Research

Sep 02, 2026

Aug 29, 2026

ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Aug 29, 2026

Aug 28, 2026

ProQR Therapeutics (NASDAQ:PRQR) Share Price Crosses Above 50-Day Moving AverageWhat's Next? - MarketBeat

Aug 28, 2026

Aug 25, 2026